A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers

• Published in: JNCI : Journal of the National Cancer Institute Vol. 113; no. 12; pp. 1683 - 1692
• Main Authors: Cercek, Andrea, Chatila, Walid K, Yaeger, Rona, Walch, Henry, Fernandes, Gustavo Dos Santos, Krishnan, Asha, Palmaira, Lerie, Maio, Anna, Kemel, Yelena, Srinivasan, Preethi, Bandlamudi, Chaitanya, Salo-Mullen, Erin, Tejada, Prince R, Belanfanti, Kimeisha, Galle, Jesse, Joseph, Vijai, Segal, Neil, Varghese, Anna, Reidy-Lagunes, Diane, Shia, Jinru, Vakiani, Efsevia, Mondaca, Sebastian, Mendelsohn, Robin, Lumish, Melissa A, Steinruecke, Felix, Kemeny, Nancy, Connell, Louise, Ganesh, Karuna, Markowitz, Arnold, Nash, Garrett, Guillem, Jose, Smith, J Joshua, Paty, Phillip B, Zhang, Liying, Mandelker, Diana, Birsoy, Ozge, Robson, Mark, Offit, Kenneth, Taylor, Barry, Berger, Michael, Solit, David, Weiser, Martin, Saltz, Leonard B, Aguilar, Julio Garcia, Schultz, Nikolaus, Diaz, Luis A, Stadler, Zsofia K
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 29-11-2021
• Subjects: Abdominal Pain - genetics; Adult; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - epidemiology; Colorectal Neoplasms - genetics; Genetic Testing; Humans; Incidence
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djab124

The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset colorectal cancer (AO-CRC).
Clinical, histopathologic, and genomic characteristics of EO-CRC patients (2014-2019), divided into age 35 years and younger and 36-49 years at diagnosis, were compared with AO-CRC (50 years and older). Patients with mismatch repair deficient tumors, CRC-related hereditary syndromes, and inflammatory bowel disease were excluded from all but the germline analysis. All statistical tests were 2-sided.
In total, 759 patients with EO-CRC (35 years, n = 151; 36-49 years, n = 608) and AO-CRC (n = 687) were included. Left-sided tumors (35 years and younger = 80.8%; 36-49 years = 83.7%; AO = 63.9%; P < .001 for both comparisons), rectal bleeding (35 years and younger = 41.1%; 36-49 years = 41.0%; AO = 25.9%; P = .001 and P < .001, respectively), and abdominal pain (35 years and younger = 37.1%; 36-49 years = 34.0%; AO = 26.8%; P = .01 and P = .005, respectively) were more common in EO-CRC. Among microsatellite stable tumors, we found no differences in histopathologic tumor characteristics. Initially, differences in TP53 and Receptor Tyrosine Kinase signaling pathway (RTK-RAS)alterations were noted by age. However, on multivariate analysis including somatic gene analysis and tumor sidedness, no statistically significant differences at the gene or pathway level were demonstrated. Among advanced microsatellite stable CRCs, chemotherapy response and survival were equivalent by age cohorts. Pathogenic germline variants were identified in 23.3% of patients 35 years and younger vs 14.1% of AO-CRC (P = .01).
EO-CRCs are more commonly left-sided and present with rectal bleeding and abdominal pain but are otherwise clinically and genomically indistinguishable from AO-CRCs. Aggressive treatment regimens based solely on the age at CRC diagnosis are not warranted.